The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Expression of PRAME and MAGE-A3 in Asian and European patients with non-small cell lung cancer (NSCLC), bladder cancer, or hepatocellular carcinoma (HCC).
Patrick Therasse
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Albert Linder
Consultant or Advisory Role - GlaxoSmithKline (U)
Sumitra Thongprasert
Consultant or Advisory Role - Lilly (U); Novartis (U); Pfizer (U)
Honoraria - AstraZeneca; Roche
Research Funding - Novartis; Pfizer; Roche
Pan-Chyr Yang
No relevant relationships to disclose
Po-Huang Lee
No relevant relationships to disclose
Tawesak Tanwandee
No relevant relationships to disclose
Jin Hyoung Kang
No relevant relationships to disclose
Jungsin Lee
No relevant relationships to disclose
Kesavan Sittampalam
No relevant relationships to disclose
Anon Chotirosniramit
Research Funding - GlaxoSmithKline
Ross A. Soo
No relevant relationships to disclose
Hendrik Van Poppel
No relevant relationships to disclose
Evelyne Lerut
No relevant relationships to disclose
Steven Joniau
No relevant relationships to disclose
Thierry Coche
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Olivier Gruselle
Employment or Leadership Position - GlaxoSmithKline
Diego D'Agostino
Employment or Leadership Position - GlaxoSmithKline
Aung Myo
Employment or Leadership Position - GlaxoSmithKline
Jamila Louahed
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Research Funding - GlaxoSmithKline